Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Br J Cancer
    September 2025
  1. VAN DAM S, Krijgsman D, Kucukkose E, Verdonschot MEL, et al
    Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.
    Br J Cancer. 2025 Sep 2. doi: 10.1038/s41416-025-03137.
    >> Share

    July 2025
  2. SIMBA H, McCormack V, Bilaba J, Mmbaga BT, et al
    Non-melanoma skin cancer and HPV in persons with albinism: a call for research investment.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03107.
    >> Share

    May 2025
  3. NORINGRIIS IM, Donia M, Madsen K, Schmidt H, et al
    Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.
    Br J Cancer. 2025 May 26. doi: 10.1038/s41416-025-03048.
    >> Share

    April 2025
  4. VAN DIJK EJ, Nienhuis HH, van den Eertwegh AJM, Boers-Sonderen MJ, et al
    Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.
    Br J Cancer. 2025 Apr 29. doi: 10.1038/s41416-025-03027.
    >> Share

  5. BROCHE C, Um K, Vilgrain I, Mouret S, et al
    Soluble VE-cadherin as a biomarker of response to immunotherapy by anti-PD1 in metastatic melanoma.
    Br J Cancer. 2025 Apr 18. doi: 10.1038/s41416-025-03026.
    >> Share

  6. BLOEM M, de Meza MM, van den Eertwegh AJM, Aarts MJB, et al
    Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.
    Br J Cancer. 2025 Apr 15. doi: 10.1038/s41416-025-03021.
    >> Share

    November 2024
  7. MHAIDAT NM, Zhang XD, Allen J, Avery-Kiejda KA, et al
    Editorial Expression of Concern: Temozolomide induces senescence but not apoptosis in human melanoma cells.
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02907.
    >> Share

    October 2024
  8. CHATTOPADHYAY C, Roszik J, Bhattacharya R, Alauddin M, et al
    Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma.
    Br J Cancer. 2024 Oct 11. doi: 10.1038/s41416-024-02866.
    >> Share

  9. PUDJIHARTONO M, Pudjihartono N, O'Sullivan JM, Schierding W, et al
    Melanoma-specific mutation hotspots in distal, non-coding, promoter-interacting regions implicate novel candidate driver genes.
    Br J Cancer. 2024 Oct 4. doi: 10.1038/s41416-024-02870.
    >> Share

    August 2024
  10. ORAIOPOULOU ME, Couturier DL, Bunce EV, Cannell IG, et al
    The in vitro dynamics of pseudo-vascular network formation.
    Br J Cancer. 2024;131:457-467.
    >> Share

  11. MERRICK S, Rush HL, Daniels S, Fielding A, et al
    Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition.
    Br J Cancer. 2024;131:515-523.
    >> Share

    June 2024
  12. SCHORGHOFER D, Vock L, Mirea MA, Eckel O, et al
    Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation.
    Br J Cancer. 2024 Jun 20. doi: 10.1038/s41416-024-02758.
    >> Share

    February 2024
  13. ZAKKAK N, Barclay ME, Swann R, McPhail S, et al
    The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit.
    Br J Cancer. 2024;130:297-307.
    >> Share

    December 2023
  14. WANG S, Riedstra CP, Zhang Y, Anandh S, et al
    PTEN-restoration abrogates brain colonisation and perivascular niche invasion by melanoma cells.
    Br J Cancer. 2023 Dec 26. doi: 10.1038/s41416-023-02530.
    >> Share

  15. MAVOR ME, Hanna TP, Asai Y, Langley H, et al
    Factors associated with the melanoma diagnostic interval in Ontario, Canada: a population-based study.
    Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02518.
    >> Share

    October 2023
  16. LIU M, Dong Q, Chen B, Liu K, et al
    Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells.
    Br J Cancer. 2023;129:1339-1349.
    >> Share

  17. DONINI C, Galvagno F, Rotolo R, Massa A, et al
    PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade.
    Br J Cancer. 2023;129:1409-1416.
    >> Share

    July 2023
  18. MARIANI P, Torossian N, van Laere S, Vermeulen P, et al
    Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
    Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02331.
    >> Share

    March 2023
  19. RODRIGUES A, Cosman R, Joshua AM
    Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress.
    Br J Cancer. 2023 Mar 28. doi: 10.1038/s41416-023-02231.
    >> Share

  20. RODRIGUES A, Cosman R, Joshua AM
    LXS196 for Metastatic Uveal Melanoma - finally some progress.
    Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02199.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016